Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases

Background Growth in development, approvals, and revenue of drugs treating rare diseases (orphan drugs) has been increasing over the last four decades, which has drawn substantial attention to these products. Much of this growth has been attributed to the incentives created by the Orphan Drug Act, w...

Ausführliche Beschreibung